- Home
- GBLI vs CLLS Comparison
GBLI vs CLLS Comparison
Compare GBLI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBLI | CLLS |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.4M | 384.3M |
| IPO Year | 2010 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GBLI | CLLS |
|---|---|---|
| Price | $26.79 | $3.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 1.2K | ★ 25.8K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $450,098,000.00 | N/A |
| Revenue This Year | $14.23 | N/A |
| Revenue Next Year | $9.68 | $0.98 |
| P/E Ratio | $15.54 | ★ N/A |
| Revenue Growth | ★ 2.02 | N/A |
| 52 Week Low | $25.88 | $1.33 |
| 52 Week High | $34.00 | $5.48 |
Technical Indicators
Market Signals| Indicator | GBLI | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.24 | 51.02 |
| Support Level | $25.88 | $3.39 |
| Resistance Level | $29.37 | $4.54 |
| Average True Range (ATR) | 0.73 | 0.15 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 45.46 | 23.81 |
Price Performance
Historical ComparisonAbout GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.